dabrafenid

GlaxoSmithKline Begins Phase 3 Melanoma Study
Motley Fool
Mon, 02/4/13 - 11:24 am
GSK
melanoma
BRAF inhibitor
dabrafenid
MEK inhibitor
trametinib